Mathias B Forrester1. 1. Texas Department of State Health Services, Austin, Texas 78756, USA. mathias.forrester@dshs.state.tx.us
Abstract
INTRODUCTION: Little data exist on potentially adverse valsartan ingestions reported to poison control centers. METHODS: Using adult ingestions of valsartan reported to Texas poison control centers during 2000-2005, I determined the proportion of cases involving serious outcomes for selected variables and evaluated for statistical significance by calculating the rate ratio (RR) and 95% confidence interval (CI). RESULTS: Thirteen (7%) of 185 total cases involved serious outcomes. Serious outcomes were significantly more likely to occur with a maximum dose 320 mg (RR 9.06, CI 1.30-100.14) or 4 tablets (RR 9.00, CI 2.07-39.11) or where the circumstances of the exposures involved self-harm or malicious intent (RR 17.28, CI 4.98-67.13). CONCLUSIONS: The severity of the medical outcome associated with adult valsartan ingestions depended on the dose and the circumstances of the ingestion. Such information is useful for creating triage guidelines for the management of adult valsartan ingestions.
INTRODUCTION: Little data exist on potentially adverse valsartan ingestions reported to poison control centers. METHODS: Using adult ingestions of valsartan reported to Texas poison control centers during 2000-2005, I determined the proportion of cases involving serious outcomes for selected variables and evaluated for statistical significance by calculating the rate ratio (RR) and 95% confidence interval (CI). RESULTS: Thirteen (7%) of 185 total cases involved serious outcomes. Serious outcomes were significantly more likely to occur with a maximum dose 320 mg (RR 9.06, CI 1.30-100.14) or 4 tablets (RR 9.00, CI 2.07-39.11) or where the circumstances of the exposures involved self-harm or malicious intent (RR 17.28, CI 4.98-67.13). CONCLUSIONS: The severity of the medical outcome associated with adult valsartan ingestions depended on the dose and the circumstances of the ingestion. Such information is useful for creating triage guidelines for the management of adult valsartan ingestions.
Authors: William A Watson; Toby L Litovitz; Wendy Klein-Schwartz; George C Rodgers; Jessica Youniss; Nicole Reid; Wayne G Rouse; Rebecca S Rembert; Douglas Borys Journal: Am J Emerg Med Date: 2004-09 Impact factor: 2.469
Authors: William A Watson; Toby L Litovitz; George C Rodgers; Wendy Klein-Schwartz; Nicole Reid; Jessica Youniss; Anne Flanagan; Kathleen M Wruk Journal: Am J Emerg Med Date: 2005-09 Impact factor: 2.469
Authors: Paul M Wax; Andrew R Erdman; Peter A Chyka; Daniel C Keyes; E Martin Caravati; Lisa Booze; Gwenn Christianson; Alan Woolf; Kent R Olson; Anthony S Manoguerra; Elizabeth J Scharman; William G Troutman Journal: Clin Toxicol (Phila) Date: 2005 Impact factor: 4.467
Authors: Kent R Olson; Andrew R Erdman; Alan D Woolf; Elizabeth J Scharman; Gwenn Christianson; E Martin Caravati; Paul M Wax; Lisa L Booze; Anthony S Manoguerra; Daniel C Keyes; Peter A Chyka; William G Troutman Journal: Clin Toxicol (Phila) Date: 2005 Impact factor: 4.467
Authors: Marc A Pfeffer; John J V McMurray; Eric J Velazquez; Jean-Lucien Rouleau; Lars Køber; Aldo P Maggioni; Scott D Solomon; Karl Swedberg; Frans Van de Werf; Harvey White; Jeffrey D Leimberger; Marc Henis; Susan Edwards; Steven Zelenkofske; Mary Ann Sellers; Robert M Califf Journal: N Engl J Med Date: 2003-11-10 Impact factor: 91.245